Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Delamanid: first global approval.

Literature DB >> 24923253

Delamanid: first global approval.

Nicola J Ryan¹, Jin Han Lo.
1. Adis, Auckland, New Zealand.

Abstract

Delamanid, a nitro-dihydro-imidazooxazole derivative, has been developed by Otsuka Pharmaceutical for the treatment of multidrug-resistant tuberculosis (MDR-TB). Delamanid received its first global approval for the treatment of MDR-TB in the European Union (EU), for use in combination with optimised background therapy. It is also under review for marketing in Japan for MDR-TB, the first drug application filed in Japan for this indication. Delamanid has been granted orphan drug status in both the EU and Japan. This article summarizes the milestones in the development of delamanid leading to this first approval for MDR-TB.

Entities: Chemical Disease

Mesh：

Substances：

Year: 2014 PMID： 24923253 DOI： 10.1007/s40265-014-0241-5

Source DB: PubMed Journal: Drugs ISSN： 0012-6667 Impact factor: 9.546

10 in total

Review 1. New drugs against tuberculosis: problems, progress, and evaluation of agents in clinical development.

Authors: Jossy van den Boogaard; Gibson S Kibiki; Elton R Kisanga; Martin J Boeree; Rob E Aarnoutse
Journal: Antimicrob Agents Chemother Date: 2008-12-15 Impact factor: 5.191

Review 2. Tuberculosis: the drug development pipeline at a glance.

Authors: Baptiste Villemagne; Céline Crauste; Marion Flipo; Alain R Baulard; Benoit Déprez; Nicolas Willand
Journal: Eur J Med Chem Date: 2012-02-25 Impact factor: 6.514

3. Clinical benefit of delamanid (OPC-67683) in the treatment of multidrug-resistant tuberculosis patients in China.

Authors: Qing Zhang; Yidian Liu; Shenjie Tang; Wei Sha; Heping Xiao
Journal: Cell Biochem Biophys Date: 2013 Impact factor: 2.194

4. Early bactericidal activity of delamanid (OPC-67683) in smear-positive pulmonary tuberculosis patients.

Authors: A H Diacon; R Dawson; M Hanekom; K Narunsky; A Venter; N Hittel; L J Geiter; C D Wells; A J Paccaly; P R Donald
Journal: Int J Tuberc Lung Dis Date: 2011-07 Impact factor: 2.373

Review 5. Drugs in development for tuberculosis.

Authors: Ann M Ginsberg
Journal: Drugs Date: 2010-12-03 Impact factor: 9.546

Review 6. New treatment options for multidrug-resistant tuberculosis.

Authors: Stephen K Field; Dina Fisher; Julie M Jarand; Robert L Cowie
Journal: Ther Adv Respir Dis Date: 2012-07-04 Impact factor: 4.031

7. Delamanid for multidrug-resistant pulmonary tuberculosis.

Authors: Maria Tarcela Gler; Vija Skripconoka; Epifanio Sanchez-Garavito; Heping Xiao; Jose L Cabrera-Rivero; Dante E Vargas-Vasquez; Mengqiu Gao; Mohamed Awad; Seung-Kyu Park; Tae Sun Shim; Gee Young Suh; Manfred Danilovits; Hideo Ogata; Anu Kurve; Joon Chang; Katsuhiro Suzuki; Thelma Tupasi; Won-Jung Koh; Barbara Seaworth; Lawrence J Geiter; Charles D Wells
Journal: N Engl J Med Date: 2012-06-07 Impact factor: 91.245

8. Bactericidal activity of OPC-67683 against drug-tolerant Mycobacterium tuberculosis.

Authors: Oluwabunmi Y Saliu; Catina Crismale; Stephan K Schwander; Robert S Wallis
Journal: J Antimicrob Chemother Date: 2007-08-29 Impact factor: 5.790

9. Delamanid improves outcomes and reduces mortality in multidrug-resistant tuberculosis.

Authors: Vija Skripconoka; Manfred Danilovits; Lea Pehme; Tarmo Tomson; Girts Skenders; Tiina Kummik; Andra Cirule; Vaira Leimane; Anu Kurve; Klavdia Levina; Lawrence J Geiter; Davide Manissero; Charles D Wells
Journal: Eur Respir J Date: 2012-09-27 Impact factor: 16.671

10. OPC-67683, a nitro-dihydro-imidazooxazole derivative with promising action against tuberculosis in vitro and in mice.

Authors: Makoto Matsumoto; Hiroyuki Hashizume; Tatsuo Tomishige; Masanori Kawasaki; Hidetsugu Tsubouchi; Hirofumi Sasaki; Yoshihiko Shimokawa; Makoto Komatsu
Journal: PLoS Med Date: 2006-11 Impact factor: 11.069

10 in total

39 in total

1. Synthesis and Biological Evaluation of Polar Functionalities Containing Nitrodihydroimidazooxazoles as Anti-TB Agents.

Authors: Kushalava Reddy Yempalla; Gurunadham Munagala; Samsher Singh; Gurleen Kour; Shweta Sharma; Reena Chib; Sunil Kumar; Priya Wazir; G D Singh; Sushil Raina; Sonali S Bharate; Inshad Ali Khan; Ram A Vishwakarma; Parvinder Pal Singh
Journal: ACS Med Chem Lett Date: 2015-09-11 Impact factor: 4.345

Review 2. New agents for the treatment of drug-resistant Mycobacterium tuberculosis.

Authors: Daniel T Hoagland; Jiuyu Liu; Robin B Lee; Richard E Lee
Journal: Adv Drug Deliv Rev Date: 2016-05-02 Impact factor: 15.470

3. Identification of Better Pharmacokinetic Benzothiazinone Derivatives as New Antitubercular Agents.

Authors: Kai Lv; Xuefu You; Bin Wang; Zengquan Wei; Yun Chai; Bo Wang; Apeng Wang; Guocheng Huang; Mingliang Liu; Yu Lu
Journal: ACS Med Chem Lett Date: 2017-05-10 Impact factor: 4.345

Review 4. Shwachman-Diamond Syndrome: Molecular Mechanisms and Current Perspectives.

Authors: Valentino Bezzerri; Marco Cipolli
Journal: Mol Diagn Ther Date: 2019-04 Impact factor: 4.074

Review 5. Potential anti-TB investigational compounds and drugs with repurposing potential in TB therapy: a conspectus.

Authors: Adetomiwa A Adeniji; Kirsten E Knoll; Du Toit Loots
Journal: Appl Microbiol Biotechnol Date: 2020-05-05 Impact factor: 4.813

6. Pentacyanoferrate(II) complex of pyridine-4- and pyrazine-2-hydroxamic acid as source of HNO: investigation of anti-tubercular and vasodilation activities.

Authors: Edinilton Muniz Carvalho; Tercio de Freitas Paulo; Alix Sournia Saquet; Bruno Lopes Abbadi; Fernanda Souza Macchi; Cristiano Valim Bizarro; Rafael de Morais Campos; Talles Luann Abrantes Ferreira; Nilberto Robson Falcão do Nascimento; Luiz Gonzaga França Lopes; Remi Chauvin; Eduardo Henrique Silva Sousa; Vania Bernardes-Génisson
Journal: J Biol Inorg Chem Date: 2020-07-29 Impact factor: 3.358